Stockscreener 앱 받기
62.55
2.88%
1.75
시간 외 거래:
62.55
전일 마감가:
$60.80
열려 있는:
$60.8
하루 거래량:
462.28K
Relative Volume:
0.78
시가총액:
$2.69B
수익:
$535.08M
순이익/손실:
$-48.27M
주가수익비율:
-55.18
EPS:
-1.1335
순현금흐름:
$-31.54M
1주 성능:
+2.09%
1개월 성능:
+0.11%
6개월 성능:
-19.57%
1년 성능:
+58.68%
1일 변동 폭
$60.51
$63.04
1주일 범위
$60.08
$64.59
52주 변동 폭
$38.51
$85.25
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
명칭
Tarsus Pharmaceuticals Inc
전화
(949) 409-9820
주소
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
62.55 | 2.66B | 535.08M | -48.27M | -31.54M | -1.1335 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-24 | 재개 | Oppenheimer | Outperform |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-11-20 | 개시 | Mizuho | Outperform |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-27 | 재개 | H.C. Wainwright | Buy |
| 2023-11-20 | 개시 | Goldman | Neutral |
| 2023-07-18 | 개시 | William Blair | Outperform |
| 2023-05-18 | 개시 | Guggenheim | Buy |
| 2022-08-01 | 개시 | Barclays | Overweight |
| 2021-12-21 | 개시 | H.C. Wainwright | Buy |
| 2021-11-23 | 개시 | Oppenheimer | Outperform |
| 2020-11-10 | 개시 | BofA Securities | Buy |
| 2020-11-10 | 개시 | Jefferies | Buy |
| 2020-11-10 | 개시 | Ladenburg Thalmann | Buy |
| 2020-11-10 | 개시 | Raymond James | Strong Buy |
모두보기
Tarsus Pharmaceuticals Inc 주식(TARS)의 최신 뉴스
Tarsus Pharmaceuticals (NASDAQ: TARS) insider files to sell 12,500 shares - Stock Titan
[144] Tarsus Pharmaceuticals, Inc. SEC Filing - Stock Titan
Tarsus Pharmaceuticals, Inc. Q1 2026 earnings preview - MSN
Is Conference-Spotlighted XDEMVY Adoption Quietly Reshaping the Long-Term Narrative for Tarsus (TARS)? - Sahm
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Strong Longer Term Returns - Sahm
A Look At Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Strength And Perceived Discount - Yahoo Finance
Clearbridge Investments LLC Cuts Stake in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Understanding the Setup: (TARS) and Scalable Risk - Stock Traders Daily
Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded to Buy at Wall Street Zen - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Autolus Therapeutics (AUTL), Wuxi Biologics (Cayman) (WXIBF) - The Globe and Mail
TARS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
William Blair Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating - Moomoo
Evaluating Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness - Sahm
Tarsus Pharmaceuticals (TARS) Holds Steady Near $59 as Consolidation ContinuesJurik MA - newsline.com
Tarsus Pharmaceuticals (TARS) Holds Steady Near Support as Market Watches Key LevelsPre-Earnings Momentum - newsline.com
Tarsus to Participate in Upcoming Investor Conferences - GlobeNewswire
Tarsus Pharmaceuticals (TARS) Gets a Buy from H.C. Wainwright - The Globe and Mail
The Technical Signals Behind (TARS) That Institutions Follow - Stock Traders Daily
Tarsus Pharmaceuticals (TARS) Shows Resilience Near Support After Moderate DeclineBull Pennant - The Legal Advocate
H.C. Wainwright Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $88 - Moomoo
Tarsus Pharmaceuticals (TARS) Sees Minor Pullback as Traders Eye Support ZoneDeath Cross - newsline.com
Assessing Tarsus Pharmaceuticals (TARS) Valuation After New TP-05 Phase 2b Lyme Disease Trial Update - Sahm
Tarsus Advances TP-05 Lyme Prevention Trial, Setting Up a New Mid-Stage Catalyst for TARS Investors - TipRanks
John Cena hops into the ring to fight demodex blepharitis for Tarsus Pharmaceuticals - Medical Marketing and Media
Tarsus, RxSight Fall Despite Growth Signals - Orange County Business Journal
Precision Trading with Tarsus Pharmaceuticals Inc. (TARS) Risk Zones - Stock Traders Daily
Janus Henderson holds 2.24M shares in Tarsus Pharmaceuticals (TARS) - Stock Titan
Tarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance Raise (NASDAQ:TARS) - Seeking Alpha
Deep Track entities report 3.6M shares in Tarsus (NASDAQ: TARS) - Stock Titan
Did Tarsus’ (TARS) Surge in Q1 Revenue and Narrower Loss Just Shift Its Investment Narrative? - Sahm
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Tarsus and John Cena Partner to Raise Awareness of Demodex - GlobeNewswire
Number of shareholders of Tarsus Pharmaceuticals, Inc. – NASDAQ:TARS - TradingView
Number of shareholders of Tarsus Pharmaceuticals, Inc. – BX:TARS - TradingView
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Long Term Gains - Yahoo Finance
Is It Time To Reassess Tarsus Pharmaceuticals (TARS) After Its Recent Share Price Swings? - Yahoo Finance
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Pipeline Growth Expectations - Sahm
Lifesci Capital Has Negative Estimate for TARS Q2 Earnings - MarketBeat
What is HC Wainwright's Estimate for TARS Q2 Earnings? - MarketBeat
Tarsus Pharmaceuticals Earnings Call Signals Durable Growth - TipRanks
Vanguard Group Inc. Purchases 127,470 Shares of Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus reiterates 2026 net product sales guidance of $670M-$700M as XDEMVY posts $145.4M in Q1 sales - MSN
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $90 - Moomoo
Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100 - Moomoo
LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $95 - Moomoo
Prudential subsidiaries hold 1.84M Tarsus shares (NASDAQ: TARS) - Stock Titan
A Quick Look at Today's Ratings for Tarsus Pharmaceuticals(TARS.US), With a Forecast Between $88 to $95 - Moomoo
Tarsus Pharmaceuticals Reports Revenue Increase in Q1 Driven by Xdemvy - VisionMonday.com
Tarsus Pharmaceuticals (TARS) Reports Strong Q1 2026 Earnings Dr - GuruFocus
Three Tarsus conference webcasts are set for May, with replays to follow - Stock Titan
Q1 2026 Tarsus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Tarsus Pharmaceuticals Inc (TARS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):